Category: biotech

.Veteran equity capital firm venBio has actually raised an additional half a billion bucks to invest in biotechs focusing on diseases along with unmet need.

.After revealing a period 3 launch based upon positive midstage results, iTeos and GSK are eventually discussing the highlights coming from the stage 2 TIGIT

.Zevra Rehabs’ unusual health condition medication seems to be on the pathway to approval this fall after getting the backing of an FDA consultatory committee,

.Otsuka Drug’s renal health condition drug has actually hit the main endpoint of a phase 3 test by showing in an acting analysis the decrease

.Bicara Therapies and also Zenas Biopharma have actually delivered clean motivation to the IPO market along with filings that highlight what freshly public biotechs might

.CEO David Ricks may view the business setting up tents at basecamp responsible for Eli Lilly in an attempt to get a niche of the

.After increasing $213 thousand in 2023– one of the year’s largest personal biotech rounds– Volume Biosciences is actually making cuts.” Even with our clear medical

.As biotechs try to switch a fresh page in August, at least 3 companies have dropped team in tries to forge on. First off is

.OncoC4 is actually taking AcroImmune– as well as its internal scientific manufacturing functionalities– under its wing in an all-stock merging.Each cancer biotechs were actually co-founded

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, declaring (PDF) for an IPO to stake phase 3 tests of its tissue therapy in